Analysts at Lazard Capital Markets increased their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $298.00 to $325.00 in a research report issued to clients and investors on Friday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Lazard Capital Markets’ price target points to a potential upside of 18.79% from the company’s current price.
A number of other firms have also recently commented on REGN. Analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Tuesday, September 3rd. Separately, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Tuesday, August 27th.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have issued a buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $259.94.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 5.98% on Friday, hitting $289.968. 1,007,858 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $136.13 and a 52 week high of $283.99. The stock’s 50-day moving average is $255.0 and its 200-day moving average is $230.2. The company has a market cap of $28.330 billion and a price-to-earnings ratio of 36.18.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.73 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter last year, the company posted $0.90 earnings per share. Regeneron Pharmaceuticals’s revenue was up 50.5% compared to the same quarter last year.
In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 5,000 shares of the stock on the open market in a transaction dated Monday, September 9th. The stock was sold at an average price of $275.47, for a total transaction of $1,377,350.00. The sale was disclosed in a filing with the SEC, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.